By reworking an existing protein, researchers at UC San Diego have revitalized a previously unsuccessful cancer treatment.

Antralization is considered a critical, reversible stage preceding gastric cancer. However, available biomarkers for identifying antralization are lacking. This study aimed to explore antralization-specific biomarkers in peripheral blood and gastric mucosa.

The ESMO Congress 2025 will take place from 17-21 October in Berlin, Germany, where internationally renowned oncology experts will present cutting-edge data and engage in thought-provoking discussions covering the current advances and future directions of oncology research and care.

Researchers from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB), led by an internationally recognised stem cell expert, have identified markers of two critical stem cell populations that drive colorectal cancer formation. The breakthrough study, published in Nature Cell Biology, reveals how NOX1 and NPY1R proteins mark distinct stem cell populations in different colon regions that serve as the origins of colorectal cancer, providing new targets and models for developing region-specific cancer treatments.

This review synthesizes the utility of exhaled volatile organic compounds (VOCs) in cancer diagnosis, treatment efficacy prediction, and recurrence monitoring. As endogenous metabolic byproducts, VOCs enable noninvasive detection via technologies like gas chromatography-mass

spectrometry (GC-MS), electronic noses, selected ion flow tube mass spectrometry (SIFT-MS), and high-pressure photonionization time-of-flight mass spectrometry (HPPI-TOFMS).

Key findings include strong diagnostic performance (e.g., lung cancer AUC=0.95, hepatocellular carcinoma VOC sensitivity outperforming AFP)，accurate prediction of anti-PD-1/PD-L1 therapy response (AUC=0.89–0.97), and utility in colorectal cancer postoperative recurrence surveillance. Innovatively, it links VOC alterations to mechanisms (oxidative stress, CYP450 overexpression) and compares detection technologies’ strengths/limitations.

Clinical implications: VOCs address gaps of traditional biomarkers (low sensitivity/specificity)， while highlighting needs for standardized sampling/analysis protocols and improved device stability to advance clinical translation.

Most scientific data never fuel the discoveries they should. 

For every 100 datasets created, around 80 remain in the lab, 20 are shared but rarely reused, fewer than two meet FAIR standards, and only one typically drives new findings. 

The result: delayed cancer treatments, climate models short on evidence, and research that cannot be reproduced. 

Frontiers, the open-science publisher, is tackling this problem with the launch of Frontiers FAIR² Data Management, the world’s first all-in-one, AI-powered service for research data. Designed to transform how data is shared so it is reusable and credited, it brings together curation, compliance checks, AI-ready packaging, peer review, an interactive portal, certification, and lifetime hosting in a single workflow — ensuring that research funded today delivers faster breakthroughs in health, sustainability, and technology tomorrow.